Bispecific CD19-directed CD3-directed T Cell Engager
This page covers all Bispecific CD19-directed CD3-directed T Cell Engager drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting B-lymphocyte antigen CD19.
Targets
Marketed (1)
- Blincyto · Amgen · Oncology · 1000
Blincyto works by binding to both T cells and cancer cells, directing the T cells to kill the cancer cells.
Patent intelligence
- bispecific cd19 directed cd3 directed t cell engager patent landscape — aggregated cliff calendar, attackable patents, originator estates